NRX Pharmaceuticals, Inc. (NRXP) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
No case yet. It builds on the next filing, report or 13F period.
NRX Pharmaceuticals, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
High 3.42 at 9:00 am ET, low 3.33 at 11:30 am ET.
NRX Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
48 managers report a position worth $49.8M between them, and 8 of them hold 80% of it.
NRXP (NRX Pharmaceuticals, Inc.) has 2 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.